Fundraising Fox
Cognito TX
Cambridge, US · Founded 2016 · 69 employees on LinkedIn · 2 known investors
Find your way into Cognito TX
694 people in our graph share verified history with the Cognito TX team — schools, employers, funds. One of them is your warm intro.
Morgan Odellunlockedknows Steve Worthy · together at Inventiv Health (overlapped)
×6knows the team · via Aetion
×5knows the team · via Eli Lilly and Company
Cognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.
Founders & leadership
Cognito TX was founded in 2016 by Ed Boyden and Li-Huei Tsai.
CH
Christian HowellChief Executive OfficerChristian Howell is CEO of Cognito Therapeutics and previously spent nearly 15 years at Medtronic leading its Value-Based Health Care Partnerships organization and overseeing P&L for its Integrated Health Solutions program, as well as roles in business development and product management across the medical device sector. He also served as an officer in the U.S. Navy early in his career and held positions at Aetion in medical device and diagnostics verticals.
RK
Ralph KernChief Medical OfficerRalph Kern is Chief Medical Officer at Cognito Therapeutics, where he focuses on neurodegenerative disease treatment. He has held roles in academic medicine and biotechnology spanning multiple decades.
SW
Steve WorthyChief Business & Financial OfficerSteve Worthy is Chief Business & Financial Officer at Cognito Therapeutics, a neurological therapeutics company developing non-invasive sensory stimulation technology to treat neurodegenerative diseases. He brings healthcare executive experience focused on business strategy and health outcomes.
TF
Thomas FaganEVP, Neurodegenerative PortfolioThomas Fagan is EVP of the Neurodegenerative Portfolio at Cognito Therapeutics. He has held cross-functional leadership roles in product development, commercialization, and business development across pharmaceutical, medical device, and diagnostic companies.
Investors · 2
Related companies · 5
Cognition TherapeuticsCognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.
CognisionCognision develops an objective measurement system for evaluating patients with cognitive disorders including concussion, mTBI, and dementia, serving clinicians, pharmaceutical companies, and researchers through brain-based biomarkers and qEEG/ERP testing.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
CognixionCognixion develops non-invasive brain-computer interfaces and adaptive assistive technology that provide communication and control for people with complex disabilities. Its multimodal systems combine intent, context, and accessible spatial computing across interfaces such as the Apple Vision Pro.
CognigenicsCognigenics is developing iRNAi, a non-invasive intranasal RNA interference platform that delivers programmable RNA therapeutics directly to targeted brain circuits, bypassing the blood-brain barrier to modulate mood, memory, and cognition. The company focuses on precision neuropsychiatry and treatments for neurological and psychiatric disorders.
Companies working in the same space as Cognito TX.
Frequently asked questions
- What does Cognito TX do?
- Cognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.
- Who founded Cognito TX?
- Cognito TX was founded by Ed Boyden, Li-Huei Tsai in 2016.
- Who are Cognito TX's investors?
- Cognito TX's investors include FoundersX Ventures, OPAMP CAPITAL.
- Where is Cognito TX headquartered?
- Cognito TX is headquartered in Cambridge, US.